Microbiome-Derived Liquid Biopsy: New Hope for Cancer Screening?

Rachel C. Newsome,Christian Jobin

DOI: https://doi.org/10.1093/clinchem/hvaa240

IF: 12.114

2020-11-30

Clinical Chemistry

Abstract:Cancer is second leading cause of death in the United States, and part of improving survival outcomes is early detection and treatment. Assessment of molecular pathology is critical for cancer treatment, as tumor grade and metastatic potential determines therapeutic modality and likelihood of efficacy. Tissue-based analyses using tumor biopsies are limited by their availability and narrow scope of sampling (i.e., only one small section of a large, heterogeneous or metastatic tumor). Recent technology uses circulating tumor DNA, termed cell-free tumor DNA (ctDNA), that is present in body fluids (blood plasma, urine, spinal fluid) from dead cancer cells to assay for cancer type and grade. The advantage of liquid biopsies like ctDNA is that the DNA is reflective of both local tumors and distant metastatic sites, and that multiple samples can be taken non-invasively. However, these assays are only effective for tumor types with a high mutational burden, require complex analysis and are associated with high false positive/negative rates. Recent work in the microbiome space has suggested that fecal microbial composition and metabolites have predictive features in both colorectal cancer (CRC) and response to chemotherapy or immunotherapy (1). Previous efforts have been made to use the fecal microbiota signature as a non-invasive diagnostic and prognostic tool for CRC, however, the application to broader cancer types has not been attempted. Thus, the diagnostic power of microbiota still remains unclear, but represents an area of particular interest for both identifying biomarkers of disease and therapeutic response.

medical laboratory technology